This is a multicenter, open-label, single-arm, non-interventional study to investigate the treatment patterns of Neratinib in HER2-positive early-stage breast cancer in China
Study Type
OBSERVATIONAL
Enrollment
500
Neratinib standard dose 240 mg once daily for 1 year
Medical Affair
Shanghai, China
Duration of Treatment
Median duration of extended adjuvant treatment with neratinib
Time frame: 12 months of treatment
Treatment holds and permanent discontinuations time
Median treatment holds and permanent discontinuations time
Time frame: 12 months of treatment
Patient demographics
% of patients with different demographic characteristics
Time frame: Baseline
Patient characteristics
% of patients with different disease characteristics
Time frame: Baseline
Time to treatment
Median time to treatment since completion of adjuvant regimen
Time frame: Baseline
Prior adjuvant treatments
% of patients with different prior adjuvant treatments
Time frame: Baseline
Dose adjustments
% of patients with dose adjustments
Time frame: 12 months of treatment
Dose intensity
Absolute and relative dose intensity
Time frame: 12 months of treatment
Concomitant medication
% of patients with different concomitant medications
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 12 months of treatment
Incidence of AESI
Incidence of all grades of adverse events of special interest (AESI)
Time frame: 12 months of treatment
Type of AESI
% of different type of all grades of adverse events of special interest (AESI)
Time frame: 12 months of treatment
Severity of AESI
% of patients with adverse events by severity
Time frame: 12 months of treatment
action taken for AESI
% of patients with action taken against adverse events
Time frame: 12 months of treatment